| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 9 antagonist | 2.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Not yet recruiting | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | Waldenstrom macroglobulinemia | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | breast cancer | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | systemic lupus erythematosus | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | habitual abortion | Toll-like receptor 9 antagonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | cutaneous melanoma | Toll-like receptor 9 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | non-small cell lung carcinoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | viral pneumonia | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | hepatocellular carcinoma | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | glioblastoma multiforme | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | Cutaneous T-cell lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | lung cancer | Toll-like receptor 9 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | neoplasm | Toll-like receptor 9 antagonist | 1.0 | Active, not recruiting | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | melanoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | chronic lymphocytic leukemia | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | respiratory failure | Toll-like receptor 9 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic adenocarcinoma | Toll-like receptor 9 antagonist | 1.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 1.0 | Terminated | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | chronic lymphocytic leukemia | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| BAZLITORAN | Unknown | psoriasis | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | ovarian cancer | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | neoplasm of mature B-cells | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Lyme disease | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | malaria | Toll-like receptor 9 antagonist | 4.0 | - | DailyMed,ATC |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | IGA glomerulonephritis | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Digestive System Carcinoma | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 4.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | IGA glomerulonephritis | Toll-like receptor 9 antagonist | 4.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | respiratory failure | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | prostate cancer | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | lymphangioleiomyomatosis | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | ulcerative colitis | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | cutaneous lupus erythematosus | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cholangiocarcinoma | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | adult acute respiratory distress syndrome | Toll-like receptor 9 antagonist | 3.0 | Terminated | ClinicalTrials |
| TILSOTOLIMOD SODIUM | Unknown | melanoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| BAZLITORAN | Unknown | Waldenstrom macroglobulinemia | Toll-like receptor 9 antagonist | 1.0 | Terminated | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | breast neoplasm | Toll-like receptor 9 agonist | 2.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | prediabetes syndrome | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | autoimmune thrombocytopenic purpura | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Suspended | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | obesity | Toll-like receptor 9 antagonist | 4.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | systemic lupus erythematosus | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | temporal arteritis | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 3.0 | Terminated | ClinicalTrials |
| TILSOTOLIMOD | Unknown | metastatic melanoma | Toll-like receptor 9 agonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 4.0 | Enrolling by invitation | ClinicalTrials |
| 1018 ISS | Unknown | COVID-19 | Toll-like receptor 9 agonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | severe acute respiratory syndrome | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | severe acute respiratory syndrome | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | melanoma | Toll-like receptor 9 agonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 4.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 9 antagonist | 2.0 | Unknown status | ClinicalTrials |
| 1018 ISS | Unknown | Yersinia pestis infectious disease | Toll-like receptor 9 agonist | 2.0 | Recruiting | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | esophageal cancer | Toll-like receptor 9 agonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pulmonary sarcoidosis | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 4.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cutaneous melanoma | Toll-like receptor 9 antagonist | 0.5 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | renal cell carcinoma | Toll-like receptor 9 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | malaria | Toll-like receptor 9 antagonist | 0.5 | Enrolling by invitation | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | cancer | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | Plasmodium falciparum malaria | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 3.0 | Not yet recruiting | ClinicalTrials |
| 1018 ISS | Unknown | COVID-19 | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic adenocarcinoma | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | non-small cell lung carcinoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Sjogren syndrome | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | infection | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | hidradenitis suppurativa | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | follicular lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | coronavirus infectious disease | Toll-like receptor 9 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | mucosal melanoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | non-Hodgkins lymphoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | prostate cancer | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | viral pneumonia | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| EMD-1201081 | Unknown | colorectal carcinoma | Toll-like receptor 9 agonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cancer | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | chronic hepatitis C virus infection | Toll-like receptor 9 antagonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | low grade glioma | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | viral pneumonia | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | prostate cancer | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | myelodysplastic syndrome | Toll-like receptor 9 antagonist | 1.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | rheumatic disease | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cancer | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | severe acute respiratory syndrome | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | non-small cell lung carcinoma | Toll-like receptor 9 agonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Digestive System Carcinoma | Toll-like receptor 9 antagonist | 1.0 | Active, not recruiting | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | prostate cancer | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| COBITOLIMOD | Protein | ulcerative colitis | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | coronavirus infectious disease | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | retinitis pigmentosa | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 1.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | systemic lupus erythematosus | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| 1018 ISS | Unknown | HIV infection | Toll-like receptor 9 agonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Graves ophthalmopathy | Toll-like receptor 9 antagonist | 4.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | antiphospholipid syndrome | Toll-like receptor 9 antagonist | 2.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | viral pneumonia | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | mycosis fungoides | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | carcinoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | coronary artery disease | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | MALT lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic adenocarcinoma | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| COBITOLIMOD | Protein | ulcerative colitis | Toll-like receptor 9 agonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | breast cancer | Toll-like receptor 9 antagonist | 1.0 | Active, not recruiting | ClinicalTrials |
| 1018 ISS | Unknown | COVID-19 | Toll-like receptor 9 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cutaneous melanoma | Toll-like receptor 9 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | multiple myeloma | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | sarcoma | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | HIV infection | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | antiphospholipid syndrome | Toll-like receptor 9 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 4.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | severe acute respiratory syndrome | Toll-like receptor 9 antagonist | 3.0 | Terminated | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | non-small cell lung carcinoma | Toll-like receptor 9 agonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | neoplasm | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| LEFITOLIMOD | Unknown | HIV-1 infection | Toll-like receptor 9 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Sjogren syndrome | Toll-like receptor 9 antagonist | 4.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | colorectal carcinoma | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | prostate cancer | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | interstitial lung disease | Toll-like receptor 9 antagonist | 2.0 | Suspended | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pneumonia | Toll-like receptor 9 antagonist | 3.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | interstitial lung disease | Toll-like receptor 9 antagonist | 0.5 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | obesity | Toll-like receptor 9 antagonist | 4.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | hepatitis C virus infection | Toll-like receptor 9 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 4.0 | Suspended | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Crohn's disease | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 4.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | malaria | Toll-like receptor 9 antagonist | 0.5 | Enrolling by invitation | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | colorectal neoplasm | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | acute myeloid leukemia | Toll-like receptor 9 antagonist | 1.0 | Terminated | ClinicalTrials |
| BAZLITORAN | Unknown | diffuse large B-cell lymphoma | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 4.0 | - | DailyMed |
| HYDROXYCHLOROQUINE | Small molecule | chronic progressive multiple sclerosis | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | Mantle cell lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | prostate carcinoma | Toll-like receptor 9 antagonist | 0.5 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | pancreatic carcinoma | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | acute respiratory distress syndrome | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | malaria | Toll-like receptor 9 antagonist | 4.0 | - | DailyMed |
| AGATOLIMOD | Oligonucleotide | malaria | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | infection | Toll-like receptor 9 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | Cutaneous T-cell lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pregnancy | Toll-like receptor 9 antagonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | breast cancer | Toll-like receptor 9 antagonist | 1.0 | Terminated | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | chronic lymphocytic leukemia | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | Sepsis | Toll-like receptor 9 agonist | 1.0 | Terminated | ClinicalTrials |
| EMD-1201081 | Unknown | renal cell carcinoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | mycosis fungoides | Toll-like receptor 9 agonist | 1.0 | Withdrawn | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | nodal marginal zone B-cell lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | malignant glioma | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | ankylosing spondylitis | Toll-like receptor 9 antagonist | 4.0 | Not yet recruiting | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | renal cell carcinoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | carcinoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | acute respiratory distress syndrome | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 9 antagonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Zellweger syndrome | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | neoplasm | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | severe acute respiratory syndrome | Toll-like receptor 9 antagonist | 2.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | coronavirus infectious disease | Toll-like receptor 9 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | alopecia areata | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | Mantle cell lymphoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | melanoma | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | type 2 diabetes mellitus | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | HIV infection | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | multiple myeloma | Toll-like receptor 9 antagonist | 0.5 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | pancreatic adenocarcinoma | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cutaneous lupus erythematosus | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | type 2 diabetes mellitus | Toll-like receptor 9 antagonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | small cell lung carcinoma | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| 1018 ISS | Unknown | hepatitis B virus infection | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | Plasmodium falciparum malaria | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | renal cell carcinoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | HIV infection | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | cholangiocarcinoma | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | HIV infection | Toll-like receptor 9 antagonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | leukemia | Toll-like receptor 9 antagonist | 2.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 4.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 9 antagonist | 2.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pregnancy | Toll-like receptor 9 antagonist | 1.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | infection | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| COBITOLIMOD | Protein | ulcerative colitis | Toll-like receptor 9 agonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Thrombocytopenia | Toll-like receptor 9 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | antiphospholipid syndrome | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | breast cancer | Toll-like receptor 9 antagonist | 1.0 | Suspended | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | melanoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatic disease | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | diffuse large B-cell lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | interstitial lung disease | Toll-like receptor 9 antagonist | 2.0 | Suspended | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | non-Hodgkins lymphoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| TILSOTOLIMOD SODIUM | Unknown | hepatitis C virus infection | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | X-linked Alport syndrome | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | melanoma | Toll-like receptor 9 agonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | colorectal carcinoma | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | nodal marginal zone B-cell lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | malaria | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | acute respiratory distress syndrome | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | mucosal melanoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | systemic lupus erythematosus | Toll-like receptor 9 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Sjogren syndrome | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cholangiocarcinoma | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| 1018 ISS | Unknown | non-Hodgkins lymphoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | Waldenstrom macroglobulinemia | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | X-linked Alport syndrome | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| BAZLITORAN | Unknown | Waldenstrom macroglobulinemia | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | HIV infection | Toll-like receptor 9 antagonist | 2.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| TILSOTOLIMOD | Unknown | cancer | Toll-like receptor 9 agonist | 1.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | porphyria cutanea tarda | Toll-like receptor 9 antagonist | 2.0 | Unknown status | ClinicalTrials |
| TILSOTOLIMOD | Unknown | neoplasm | Toll-like receptor 9 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | melanoma | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | Mantle cell lymphoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| EMD-1201081 | Unknown | non-small cell lung carcinoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | systemic lupus erythematosus | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 4.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | Sjogren syndrome | Toll-like receptor 9 antagonist | 4.0 | Recruiting | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | neoplasm of mature B-cells | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | osteosarcoma | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | Mantle cell lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| TILSOTOLIMOD | Unknown | cancer | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | adenocarcinoma | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | neoplasm | Toll-like receptor 9 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | influenza | Toll-like receptor 9 antagonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | coronary artery disease | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | antiphospholipid syndrome | Toll-like receptor 9 antagonist | 3.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | chronic progressive multiple sclerosis | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | colorectal carcinoma | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | MALT lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cutaneous lupus erythematosus | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | lung disease | Toll-like receptor 9 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| 1018 ISS | Unknown | hepatitis B virus infection | Toll-like receptor 9 agonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 4.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pulmonary sarcoidosis | Toll-like receptor 9 antagonist | 3.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | renal cell carcinoma | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pneumocystosis | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 4.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 3.0 | Active, not recruiting | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | carcinoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | IGA glomerulonephritis | Toll-like receptor 9 antagonist | 4.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | type 1 diabetes mellitus | Toll-like receptor 9 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| TILSOTOLIMOD SODIUM | Unknown | metastatic melanoma | Toll-like receptor 9 agonist | 2.0 | Completed | ClinicalTrials |
| COBITOLIMOD | Protein | ulcerative colitis | Toll-like receptor 9 agonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic ductal adenocarcinoma | Toll-like receptor 9 antagonist | 0.5 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Not yet recruiting | ClinicalTrials |
| BAZLITORAN | Unknown | dermatomyositis | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | insulin resistance | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pneumonia | Toll-like receptor 9 antagonist | 3.0 | Recruiting | ClinicalTrials |
| 1018 ISS | Unknown | colorectal neoplasm | Toll-like receptor 9 agonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | IGA glomerulonephritis | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | esophageal cancer | Toll-like receptor 9 agonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | graft versus host disease | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | carcinoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | preeclampsia | Toll-like receptor 9 antagonist | 3.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 9 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Central Nervous System Neoplasm | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | Splenic Marginal Zone Lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 0.5 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | clear cell renal carcinoma | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 4.0 | - | DailyMed |
| HYDROXYCHLOROQUINE | Small molecule | coronavirus infectious disease | Toll-like receptor 9 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cystic fibrosis | Toll-like receptor 9 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 9 antagonist | 4.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | sarcoma | Toll-like receptor 9 antagonist | 1.0 | Recruiting | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | mycosis fungoides | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | cancer | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | breast cancer | Toll-like receptor 9 antagonist | 1.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | lichen planus | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | systemic lupus erythematosus | Toll-like receptor 9 antagonist | 4.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | follicular lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 0.5 | Suspended | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | antiphospholipid syndrome | Toll-like receptor 9 antagonist | 2.0 | Recruiting | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | mycosis fungoides | Toll-like receptor 9 agonist | 1.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | osteoarthritis, knee | Toll-like receptor 9 antagonist | 2.0 | Completed | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | Splenic Marginal Zone Lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | osteoarthritis | Toll-like receptor 9 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | lung disease | Toll-like receptor 9 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 0.5 | Suspended | ClinicalTrials |
| TILSOTOLIMOD | Unknown | melanoma | Toll-like receptor 9 agonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pregnancy | Toll-like receptor 9 antagonist | 2.0 | Withdrawn | ClinicalTrials |
| AGATOLIMOD SODIUM | Oligonucleotide | breast neoplasm | Toll-like receptor 9 agonist | 2.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Mastocytosis | Toll-like receptor 9 antagonist | 2.0 | Not yet recruiting | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | Sepsis | Toll-like receptor 9 agonist | 1.0 | Terminated | ClinicalTrials |
| AGATOLIMOD | Oligonucleotide | diffuse large B-cell lymphoma | Toll-like receptor 9 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 9 antagonist | 2.0 | Enrolling by invitation | ClinicalTrials |